In order to evaluate whether l, 25-dihydroxyvitam1n D3 [l, 25(0H)2D3] could increase the serum concentration of osteocalcin1 (BGP) in patients with post-menopausal osteoporosis, we administered 2 µg/d of 1, 25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of l, 25(0H)2D3 significantly Increased the serum concentration of 1, 25(OH)2D from 31±2 SE to 56±5 pg/ml (p<0.01). Commensurate with the rise 1n 1, 25(OH)2D was a significant Increase in BGP from 3.9±0.6 to 6.4±0.9 ng/ml (p<0.001). There were no significant changes for these parameters in the control group. It 1s concluded that short term l, 25(0H)2D3 administration is effective 1n raising BGP concentrations in patients with post-menopausal osteoporosis.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Clinical Biochemistry
- Biochemistry, medical